IDNA vs. ARKG
IDNA (iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund) and ARKG (ARK Genomic Revolution Multi-Sector ETF) are both Health & Biotech Equities funds. IDNA is passively managed, while ARKG is actively managed. Over the past 5 years, IDNA returned -8.26%/yr vs -15.45%/yr for ARKG. Their correlation of 0.85 suggests significant overlap in exposure. IDNA charges 0.47%/yr vs 0.75%/yr for ARKG.
Performance
IDNA vs. ARKG - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, IDNA achieves a 9.51% return, which is significantly lower than ARKG's 17.36% return.
IDNA
- 1D
- -2.18%
- 1M
- -2.18%
- YTD
- 9.51%
- 6M
- 10.53%
- 1Y
- 41.74%
- 3Y*
- 6.48%
- 5Y*
- -8.26%
- 10Y*
- —
ARKG
- 1D
- -2.16%
- 1M
- 12.21%
- YTD
- 17.36%
- 6M
- 14.32%
- 1Y
- 57.12%
- 3Y*
- 0.75%
- 5Y*
- -15.45%
- 10Y*
- 7.24%
IDNA vs. ARKG - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund | 9.51% | 17.26% | -0.72% | -7.63% | -42.28% | -3.98% | 54.30% | 20.83% |
ARKG ARK Genomic Revolution Multi-Sector ETF | 17.36% | 23.04% | -28.24% | 16.22% | -53.90% | -33.92% | 180.40% | 11.53% |
Correlation
The correlation between IDNA and ARKG is 0.75, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.75 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.79 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.84 |
Correlation (All Time) Calculated using the full available price history since Jun 14, 2019 | 0.85 |
The correlation between IDNA and ARKG shifts across timeframes, from 0.75 (1 year) to 0.85 (all time), reflecting how their relationship changes across market environments.
IDNA vs. ARKG - Sectors Allocation Comparison
Sectors
IDNA
ARKG
Healthcare
Industrials
-
Basic Materials
-
-
Communication Services
-
-
Consumer Cyclical
-
-
Consumer Defensive
-
-
Energy
-
-
Financial Services
-
Real Estate
-
-
Technology
-
-
Utilities
-
-
Healthcare
IDNA
ARKG
Industrials
IDNA
ARKG
-
Basic Materials
IDNA
-
ARKG
-
Communication Services
IDNA
-
ARKG
-
Consumer Cyclical
IDNA
-
ARKG
-
Consumer Defensive
IDNA
-
ARKG
-
Energy
IDNA
-
ARKG
-
Financial Services
IDNA
-
ARKG
Real Estate
IDNA
-
ARKG
-
Technology
IDNA
-
ARKG
-
Utilities
IDNA
-
ARKG
-
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
IDNA vs. ARKG — Risk / Return Rank
IDNA
ARKG
IDNA vs. ARKG - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) and ARK Genomic Revolution Multi-Sector ETF (ARKG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| IDNA | ARKG | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.71 | 1.40 | +0.32 |
Sortino ratioReturn per unit of downside risk | 2.48 | 2.08 | +0.40 |
Omega ratioGain probability vs. loss probability | 1.28 | 1.23 | +0.04 |
Calmar ratioReturn relative to maximum drawdown | 4.09 | 2.27 | +1.82 |
Martin ratioReturn relative to average drawdown | 11.79 | 5.46 | +6.33 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| IDNA | ARKG | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.71 | 1.40 | +0.32 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.29 | -0.34 | +0.05 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.18 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.10 | 0.13 | -0.04 |
Drawdowns
IDNA vs. ARKG - Drawdown Comparison
The maximum IDNA drawdown since its inception was -68.26%, smaller than the maximum ARKG drawdown of -83.59%. Use the drawdown chart below to compare losses from any high point for IDNA and ARKG.
Loading charts...
Drawdown Indicators
| IDNA | ARKG | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -68.26% | -83.59% | +15.33% |
Max Drawdown (1Y)Largest decline over 1 year | -10.66% | -27.51% | +16.85% |
Max Drawdown (3Y)Largest decline over 3 years | -29.73% | -51.96% | +22.23% |
Max Drawdown (5Y)Largest decline over 5 years | -68.26% | -80.18% | +11.92% |
Max Drawdown (10Y)Largest decline over 10 years | — | -83.59% | — |
Current DrawdownCurrent decline from peak | -46.01% | -69.58% | +23.57% |
Average DrawdownAverage peak-to-trough decline | -36.24% | -35.86% | -0.38% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.70% | 11.46% | -7.76% |
Volatility
IDNA vs. ARKG - Volatility Comparison
The current volatility for iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) is 7.24%, while ARK Genomic Revolution Multi-Sector ETF (ARKG) has a volatility of 11.89%. This indicates that IDNA experiences smaller price fluctuations and is considered to be less risky than ARKG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| IDNA | ARKG | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 7.24% | 11.89% | -4.65% |
Volatility (6M)Calculated over the trailing 6-month period | 18.21% | 29.12% | -10.91% |
Volatility (1Y)Calculated over the trailing 1-year period | 24.51% | 41.24% | -16.73% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 28.42% | 45.62% | -17.20% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 29.53% | 41.13% | -11.60% |
IDNA vs. ARKG - Expense Ratio Comparison
IDNA has a 0.47% expense ratio, which is lower than ARKG's 0.75% expense ratio.
Dividends
IDNA vs. ARKG - Dividend Comparison
IDNA's dividend yield for the trailing twelve months is around 1.08%, while ARKG has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
ARKG ARK Genomic Revolution Multi-Sector ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.62% | 0.85% | 3.14% | 0.82% | 1.34% |
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund | 1.08% | 1.18% | 0.98% | 1.04% | 0.54% | 0.70% | 0.26% | 0.80% | 0.00% | 0.00% |
Frequently Asked Questions
IDNA and ARKG have a correlation of 0.75, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ARKG has higher volatility (11.89%) compared to IDNA (7.24%). In terms of maximum drawdown, IDNA dropped -68.26% vs ARKG's -83.59%.
On 5-year performance, IDNA leads with -8.26% vs -15.45% for ARKG. On fees, IDNA is cheaper at 0.47% per year. On volatility, IDNA has been the lower-risk option at 7.24%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 5-year period, IDNA has performed better with a -8.26% return vs -15.45%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
IDNA is cheaper with a 0.47% expense ratio, compared with 0.75% for ARKG.
IDNA has the higher dividend yield at 1.08%, compared with 0.00% for ARKG.
They also come from different issuers: iShares and ARK. Their fees differ too: 0.47% for IDNA and 0.75% for ARKG.
IDNA currently has the higher Sharpe Ratio (1.71 vs 1.40), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for IDNA and ARKG
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer